Thymopentin (TP-5) potency in vivo is enhanced by slow infusion.
The in vivo activity of thymopentin in guinea pigs was assessed electromyographically 18 h after intravenous or subcutaneous injections or infusions ranging over varying periods of time. The lowest threshold dose required to establish a positive effect was obtained with a 30-60 min i.v. infusion (0.38-0.75 micrograms/kg) and we found that we needed X 5 times this dose with 30 min s.c. infusion, X 10 this dose with 10 min i.v. or s.c. infusion, X 200 this dose with bolus IV injection and X 400 this dose with bolus s.c. injection. The marked increase of potency of thymopentin with infusion should be considered in designing clinical regimens.
D000818:Animals; D004305:Dose-Response Relationship, Drug; D005260:Female; D006168:Guinea Pigs; D006728:Hormones / Q000008:administration & dosage*; D007263:Infusions, Parenteral; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008297:Male; D009469:Neuromuscular Junction / Q000187:drug effects* / Q000502:physiology; D010446:Peptide Fragments / Q000008:administration & dosage* / Q000494:pharmacology; D016305:Thymopentin; D013946:Thymopoietins / Q000008:administration & dosage* / Q000494:pharmacology; D013951:Thymus Hormones / Q000008:administration & dosage*
D006728:Hormones; D010446:Peptide Fragments; D013946:Thymopoietins; D013951:Thymus Hormones; D016305:Thymopentin